Want to see SE:ACTI full AI Analyst Report?
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr3.70 - kr14.11
Previous CloseN/A
Volume903.68K
Average Volume (3M)53.42K
Market Cap
kr115.20M
Enterprise Valuekr106.98
Total Cash (Recent Filing)kr43.90M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume44,991
30 Day Avg. Volume53,419
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces financing pressure and preserves flexibility for advancing the therapeutic pipeline. A near-zero debt-to-equity position also limits interest obligations and refinancing exposure, giving the company more capacity to pursue development priorities if funding is secured.
Narrowing Net LossesThe steady reduction in net losses indicates improving cost discipline or operating efficiency, even though profitability remains negative. If maintained, this trajectory could extend the company’s financial runway and reduce the scale of funding required to support continued clinical development.
Improving Cash BurnLower operating cash outflows suggest that cash consumption is moderating as the business progresses its programs. This does not yet create self-funding capacity, but sustained improvement would help preserve resources and make future financing needs more manageable.
Bears Say
No Revenue GenerationZero revenue means Active Biotech has not established a recurring commercial income base and remains dependent on pipeline monetization or external funding. This limits earnings visibility, weakens scalability, and leaves future financial progress contingent on successful development and partnering outcomes.
Persistent Cash ConsumptionContinued negative operating and free cash flow shows that the business is consuming rather than generating cash. Unless development programs begin producing partnership or product-related receipts, ongoing investment will require additional financial resources and may constrain execution over the medium term.
Declining Equity BaseA shrinking equity base alongside persistently negative returns signals that losses are eroding shareholder capital. If this pattern continues, the company may face greater dilution risk from future financing and less balance-sheet capacity to absorb extended development setbacks.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr3.70 and its highest was kr14.11 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr115.20M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -kr0.383 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.383 in its last earnings report. Following the earnings report the stock price went up 2.713%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―